DE60136926D1 - Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält - Google Patents

Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält

Info

Publication number
DE60136926D1
DE60136926D1 DE60136926T DE60136926T DE60136926D1 DE 60136926 D1 DE60136926 D1 DE 60136926D1 DE 60136926 T DE60136926 T DE 60136926T DE 60136926 T DE60136926 T DE 60136926T DE 60136926 D1 DE60136926 D1 DE 60136926D1
Authority
DE
Germany
Prior art keywords
cyclodextrin
glycopeptide antibiotic
composition containing
disclosed
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136926T
Other languages
English (en)
Inventor
J Kevin Judice
Jeng-Pyng Shaw
Yongqi Mu
Michael W Conner
John L Pace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of DE60136926D1 publication Critical patent/DE60136926D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60136926T 2000-05-02 2001-05-01 Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält Expired - Lifetime DE60136926D1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US20117800P 2000-05-02 2000-05-02
US21314600P 2000-06-22 2000-06-22
US21341700P 2000-06-22 2000-06-22
US21342800P 2000-06-22 2000-06-22
US21341500P 2000-06-22 2000-06-22
US21341000P 2000-06-22 2000-06-22
US22672700P 2000-08-18 2000-08-18
PCT/US2001/014000 WO2001082971A2 (en) 2000-05-02 2001-05-01 Cyclodextrin containing glycopeptide antibiotic compositions

Publications (1)

Publication Number Publication Date
DE60136926D1 true DE60136926D1 (de) 2009-01-22

Family

ID=27569291

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136926T Expired - Lifetime DE60136926D1 (de) 2000-05-02 2001-05-01 Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält

Country Status (12)

Country Link
US (5) US6858584B2 (de)
EP (1) EP1278549B1 (de)
JP (2) JP4870314B2 (de)
CN (1) CN1223378C (de)
AT (1) ATE416791T1 (de)
AU (1) AU2001259306A1 (de)
BR (1) BR0110530A (de)
CA (2) CA2408008C (de)
DE (1) DE60136926D1 (de)
ES (1) ES2316445T3 (de)
SI (1) SI1278549T1 (de)
WO (1) WO2001082971A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082971A2 (en) 2000-05-02 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI312785B (en) 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
US7499410B2 (en) * 2001-12-26 2009-03-03 Cisco Technology, Inc. Fibre channel switch that enables end devices in different fabrics to communicate with one another while retaining their unique fibre channel domain—IDs
US7599360B2 (en) * 2001-12-26 2009-10-06 Cisco Technology, Inc. Methods and apparatus for encapsulating a frame for transmission in a storage area network
GB0206930D0 (en) * 2002-03-23 2002-05-08 Univ Durham Method and apparatus for the formation of hydrophobic surfaces
US7406034B1 (en) 2002-04-01 2008-07-29 Cisco Technology, Inc. Methods and apparatus for fibre channel frame delivery
US7616637B1 (en) 2002-04-01 2009-11-10 Cisco Technology, Inc. Label switching in fibre channel networks
US7206288B2 (en) * 2002-06-12 2007-04-17 Cisco Technology, Inc. Methods and apparatus for characterizing a route in fibre channel fabric
US7433326B2 (en) 2002-11-27 2008-10-07 Cisco Technology, Inc. Methods and devices for exchanging peer parameters between network devices
JP2006528704A (ja) * 2003-05-27 2006-12-21 セラヴァンス インコーポレーテッド グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
JP2008512490A (ja) * 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
US7593324B2 (en) * 2004-10-25 2009-09-22 Cisco Technology, Inc. Graceful port shutdown protocol for fibre channel interfaces
US7916628B2 (en) * 2004-11-01 2011-03-29 Cisco Technology, Inc. Trunking for fabric ports in fibre channel switches and attached devices
EP2314599A1 (de) 2004-11-29 2011-04-27 National University Corporation Nagoya University Antibiotische Monomere Glykopeptiderivate
US7649844B2 (en) * 2004-12-29 2010-01-19 Cisco Technology, Inc. In-order fibre channel packet delivery
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US7795207B2 (en) 2005-11-21 2010-09-14 Harald Labischinski Lipopeptide compositions
DE102005056194A1 (de) * 2005-11-21 2007-07-12 Combinature Biopharm Ag Neue Lipopeptid Zusammensetzungen
NZ568288A (en) * 2005-11-28 2012-02-24 Verrow Pharmaceuticals Inc Compositions comprising a a cyclodextrin and a nephrotoxic anticancer drug
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
MX2010010998A (es) * 2008-04-07 2011-01-25 Chelsea Therapeutics Inc Composiciones de antifolato.
EP2324041A4 (de) 2008-08-13 2012-06-13 Targanta Therapeutics Corp Phosphonierte rifamycine und ihre anwendung zur vermeidung und behandlung von knochen- und gelenkinfektionen
DK2337575T3 (en) 2008-08-30 2016-05-23 Medicines Co A method of treatment with single doses of oritavancin
JP2012525391A (ja) 2009-04-28 2012-10-22 ターガンタ セラピューティクス コーポレイション オリタバンシンを用いた細菌感染の治療方法
US20110124650A1 (en) * 2009-07-08 2011-05-26 Chelsea Therapeutics, Inc. Stable crystalline salts of antifolate compounds
EP2496237A2 (de) * 2009-11-06 2012-09-12 Chelsea Therapeutics, Inc. Enzymhemmende verbindungen
US20110237609A1 (en) * 2010-03-29 2011-09-29 Chelsea Therapeutics, Inc. Antifolate compositions
WO2012078708A1 (en) 2010-12-07 2012-06-14 Chelsea Therapeutics, Inc. Combination comprising methotrexate and an antifolate compound
ES2949169T3 (es) 2013-08-26 2023-09-26 Melinta Therapeutics Inc Procedimientos para tratar la bacteriemia y la osteomielitis utilizando oritavancina
US9697843B2 (en) 2014-04-30 2017-07-04 Qualcomm Incorporated High band excitation signal generation
AU2017221435A1 (en) * 2016-02-18 2018-09-06 Melinta Therapeutics, Inc. Oritavancin formulations
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
CN107325159A (zh) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
EA201892413A1 (ru) 2016-05-09 2019-05-31 Кселлия Фармасьютикалз Апс Стабилизированные препараты гликопептидного антибиотика
CN110198959B (zh) 2017-01-03 2023-03-28 北卡罗米纳大学查佩尔希尔分校 释放一氧化氮的海藻酸盐作为可生物降解抗菌支架和相关方法
CA3055474A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
CN111511350B (zh) 2017-07-07 2023-10-13 埃皮辛特瑞柯斯公司 用于治疗剂的肠胃外施用的组合物
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
EP3762039A4 (de) 2018-03-06 2021-12-22 The University of North Carolina at Chapel Hill Stickoxidfreisetzende cyclodextrin als biologisch abbaubare antibakterielle gerüste und zugehörige verfahren
EA202092635A1 (ru) 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet
CN113383019B (zh) 2018-12-28 2023-11-17 北卡罗来纳大学教堂山分校 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法
US20220133844A1 (en) 2020-10-30 2022-05-05 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (de) 2020-12-16 2022-06-22 EVER Valinject GmbH Wässrige lösung
EP4014969A1 (de) 2020-12-16 2022-06-22 EVER Valinject GmbH Wässrige lösung

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US207797A (en) * 1878-09-10 Improvement in check-rein hooks
US229775A (en) * 1880-07-06 Eobeet h
US87494A (en) * 1869-03-02 William h
US73371A (en) * 1868-01-14 Robert moxley
US77280A (en) * 1868-04-28 John l
US63916A (en) * 1867-04-16 Improvement in cotton peess
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
DE3372705D1 (en) 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) * 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
EP0335545B2 (de) 1988-03-29 1998-09-23 University Of Florida Pharmazeutische Zusammensetzungen für die parenterale Anwendung
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
ZA909847B (en) * 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
WO1991019734A2 (en) 1990-06-15 1991-12-26 Majesty (Her) In Right Of Canada As Represented By The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
WO1993007904A1 (en) * 1991-10-16 1993-04-29 Schering Corporation Lipophilic oligosaccharide antibiotic salt compositions
IT1251751B (it) * 1991-10-31 1995-05-23 Sclavo Ricerca S R L Metodo per la coltura di microrganismi dei generi helicobacter, campylobacter e arcobacter, utilizzando terreni di coltura contenenti ciclodestrine o metil-cellulosa o loro miscele
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JPH08503951A (ja) * 1992-12-02 1996-04-30 インサイト・ビジョン・インコーポレイテッド シクロデキストリンとポリマーを用いた薬剤供給系
CA2134753A1 (en) 1993-03-08 1994-09-15 Peter K. Chiang Cyclodextrin-peptide compositions
JPH08507442A (ja) 1993-03-12 1996-08-13 セラテック，インコーポレイテッド 組換えエプスタイン−バーウイルスタンパク質およびワクチンへの使用
AU7935494A (en) 1993-10-25 1995-05-22 National Research Council Of Canada Bivalent thrombin inhibitors
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
PE40996A1 (es) 1994-01-28 1996-10-14 Lilly Co Eli Derivado de antibiotico de glucopeptido
SE510830C2 (sv) * 1995-02-16 1999-06-28 Pure Pulse Technologies Inc Sätt att med god hållbarhet förpacka färskt kött i en förpackning av plast
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
JP4215277B2 (ja) * 1996-08-09 2009-01-28 アルコン ラボラトリーズ，インコーポレイテッド シクロデキストリンを含有する薬学的組成物用防腐剤系
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US5916873A (en) * 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE323110T1 (de) * 1997-07-01 2006-04-15 Pfizer Prod Inc Verfahren zur herstellung von einem cyclodextrin
GB2344713B (en) * 1998-02-10 2003-05-07 Furuno Electric Co Display system
EP1140999A1 (de) 1998-12-23 2001-10-10 Aventis Pasteur Limited Chlamydia antigene, entsprechende dna fragmente und ihre verwendungen
NZ508594A (en) 1998-12-23 2003-05-30 Theravance Inc Glycopeptide derivatives and pharmaceutical compositions containing the same
DE19911097A1 (de) * 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
AU4054900A (en) 1999-04-02 2000-10-23 Advanced Medicine East, Inc. Desleucyl glycopeptide antibiotics and methods of making same
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
WO2001082971A2 (en) 2000-05-02 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
EP2263654B1 (de) 2000-06-21 2012-10-10 Cubist Pharmaceuticals, Inc. Arzneizusammensetzungen zum Verbessern der oralen Absorption von antimikrobiellen Wirkstoffen
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
WO2001098326A2 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
WO2001098329A1 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
WO2010004060A1 (es) * 2008-07-11 2010-01-14 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon Uso de la cilastatina para reducir la nefrotoxicidad de distintos compuestos

Also Published As

Publication number Publication date
JP4870314B2 (ja) 2012-02-08
EP1278549A2 (de) 2003-01-29
ES2316445T3 (es) 2009-04-16
SI1278549T1 (sl) 2009-04-30
US20060194717A1 (en) 2006-08-31
US6858584B2 (en) 2005-02-22
US20020077280A1 (en) 2002-06-20
CN1223378C (zh) 2005-10-19
US20050026820A1 (en) 2005-02-03
US7067483B2 (en) 2006-06-27
US7026288B2 (en) 2006-04-11
CA2408008A1 (en) 2001-11-08
CA2408008C (en) 2011-01-18
WO2001082971A3 (en) 2002-05-23
ATE416791T1 (de) 2008-12-15
US8158580B2 (en) 2012-04-17
EP1278549B1 (de) 2008-12-10
US7544364B2 (en) 2009-06-09
US20050032676A1 (en) 2005-02-10
WO2001082971A2 (en) 2001-11-08
AU2001259306A1 (en) 2001-11-12
CA2726789A1 (en) 2001-11-08
JP2008231109A (ja) 2008-10-02
US20100081609A1 (en) 2010-04-01
CN1441680A (zh) 2003-09-10
JP2003531869A (ja) 2003-10-28
BR0110530A (pt) 2003-04-08

Similar Documents

Publication Publication Date Title
ATE416791T1 (de) Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
PT759774E (pt) Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
BR9714287A (pt) Antibiótico cristalino designado solvato 6-o-metileritromicina forma 0, solvato de 6-o-metileritromicina forma 0, composição, processos para tratamento de infecções bacterianas em um mamìfero hospedeiro com necessidade de tal tratamento e para preparação de solvato de 6-o-metileritomicina a forma 0, 6-o-metileritromicina forma 0--etanolato, suspensão para administração oral, e, complexo de solvato de 6-o-metileritromicina a forma 0-carbÈmero.
EP1024145A3 (de) Neue Azalide und Verfahren zu deren Herstellung
SG153833A1 (en) Methods of treatment of endobronchial infections
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
BG104644A (en) Novel macrolides
AR034343A1 (es) Combinaciones farmaceuticas
BG105600A (en) 13-membered azalides and their use as antibiotic agents
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
EE200000587A (et) Uued 15-lülilised ketoasaliidid, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon kasutamiseks bakternakkuste ravis
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
BR0002577A (pt) Suspensões orais de trovafloxacina
DK1434779T3 (da) Tværbundne glycopeptid-cephalosporinantibiotika
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
MXPA04000337A (es) Amindioles para tratamiento de enfermedad de alzheimer.
BR0108096A (pt) Método para manter ou melhorar a sìntese de mucinas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition